Clinical trial · Observational
Establishment of a Predictive Model for Immunotherapy Response in Pancreatic Cancer
NCT07271823CI-TRIAL-00098640active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This project aims to establish a single-center, prospective, observational clinical cohort for pancreatic cancer immunotherapy. It plans to enroll 100 patients with advanced pancreatic cancer, collecting tumor tissue sections, plasma, serum, and fecal samples. Through multi-omics analysis including proteomics, metabolomics, and microbiomics, the project will develop predictive models for immunotherapy response.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer Non-resectable | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sample Collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Locally advanced or metastatic pancreatic ductal adenocarcinoma
- description
- Locally advanced or metastatic pancreatic ductal adenocarcinoma in patients who have not previously received systemic anticancer therapy
- interventionNames
- Other: Sample Collection
Primary outcomes (2)
- measure
- Objective Best Tumor Response
- timeFrame
- 12 months
- description
- Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.
- measure
- Overall Survival
- timeFrame
- 60 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age 18 years or older; 2. Histologically or cytologically confirmed locally advanced or metastatic pancreatic ductal adenocarcinoma that is unresectable; 3. No prior systemic anticancer therapy; 4. At least one measurable lesion confirmed according to RECIST 1.1 criteria; 5. Receiving first-line treatment with an immunotherapy combined with chemotherapy regimen; 6. Signed informed consent. Exclusion Criteria: 1. Active malignancy other than pancreatic cancer within the past 5 years or concurrently; 2. Prior receipt of immunotherapy or anti-angiogenic therapy.
References
Publications (0)
Data not yet available
No reference posted for this study.